COR: Specialty focus and MSO integration drive growth, with robust capital and regulatory management
Strong specialty-driven growth continues, with confidence in long-term momentum through 2027. Integration of OneOncology and RCA enhances clinical trial capabilities, while regulatory and customer dynamics remain well managed. Capital deployment focuses on growth, M&A, and shareholder returns.Based…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.